Bertis Participates in '2024 Pink Festival' to Raise Awareness of the Importance of Regular Breast Cancer Screenings- Participating as an event sponsor, operating a promotional booth to enhance breast health awareness and deliver useful information on regular breast cancer screenings, including MASTOCHECKOn October 10th, Bertis, a company specializing in proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate as a sponsor in the 2024 Pink Festival held at Yongsan Park on October 13th to conduct promotional activities highlighting the importance of regular breast cancer screenings.The Pink Festival, held as part of the Pink Ribbon Campaign, is co-hosted by the Korea Breast Cancer Foundation, the Korean Breast Cancer Society, and the Korean Cancer Association to encourage greater awareness of breast cancer and the importance of regular screenings among women. Now in its 24th year, the event will be attended by 1,000 pre-registered participants and will feature various breast health programs, including a 3km run, GX programs, consultations with medical professionals, and a mini concert.In celebration of Breast Cancer Awareness Month in October, Bertis will sponsor the 2023 Pink Festival and operate a promotional booth at the event. The booth will feature a quiz event aimed at attendees, highlighting the importance of early breast cancer detection and providing useful information about regular breast cancer screenings, including Bertis's early detection blood test, MASTOCHECK®.MASTOCHECK® is the world’s first proteomics-based early detection test for breast cancer, launched by Bertis in 2019. It has demonstrated its effectiveness in diagnosing stage 0 to 2 breast cancer and received approval from the Ministry of Food and Drug Safety in 2019. As a blood test, MASTOCHECK® can be performed on women in their 20s and 30s, for whom mammography is not recommended, and about 100,000 tests were conducted in 2023 alone. MASTOCHECK® is currently implemented in more than 500 hospitals and health screening centers in Korea.Seung-man Han, CEO of Bertis, said, “We participated in the Pink Festival to inform more women, including those in their 20s and 30s of the importance of breast health and to encourage regular breast cancer screenings. We will do our best to continuously contribute to activating early diagnosis by raising awareness and providing useful solutions based on easily accessible blood tests for the early detection of major diseases, including breast cancer, in medical settings.”

Bertis Presents Blood Test Model for Pancreatic Cancer Diagnosis with 92% Accuracy Based on 13 Biomarkers- Presenting an exploratory trial result for early diagnosis of PDAC using LC-MS technology effective for disease screening- Conducting a confirmatory trial for pancreatic cancer’s early diagnosis blood test ‘Panccheck,’ having secured blood samples from 513 individuals, including 220 pancreatic cancer patientsOn September 24th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that the findings on protein biomarkers for the diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC) were published in the September issue of the prestigious international journal ‘Molecular & Cellular Proteomics.’Pancreatic cancer is highly lethal due to its asymptomatic nature in the early stages, making early detection extremely challenging. Most patients are diagnosed at advanced stages, resulting in very low survival rates. According to data released by the Korea Central Cancer Registry in 2024, the 5-year cancer relative survival rate for pancreatic cancer from 2017 to 2021 is only 15.9%, making it the most difficult to treat among the top 10 cancers. In particular, PDAC, which accounts for more than 90% of pancreatic cancer, is considered one of the most lethal cancer types with a 5-year average survival rate of less than 10%.Currently, the blood biomarker Carbohydrate Antigen 19-9 (CA19-9) is used for pancreatic cancer screening, but its usefulness is considered limited due to its low positive predictive value. This study focused on developing an effective diagnostic method for PDAC screening based on Liquid Chromatography-Mass Spectrometry (LC-MS) technology, which allows for the simultaneous and precise quantification of multiple protein biomarkers in blood and is effective for disease screening tests that require economical and rapid analysis of a large number of samples.In this study, the Bertis research team selected 12 protein biomarkers that were differentially expressed in PDAC patients compared to a control group of healthy individuals and/or those with benign pancreatic diseases, using mass spectrometry and bioinformatics techniques. They then developed a Multi-Marker Panel consisting of 13 biomarkers combined with CA19-9. In the next step, they developed a diagnostic test model with improved performance and robustness using machine-learning technology and evaluated its diagnostic performance for PDAC screening. As a result, the model demonstrated an accuracy of 92% for all stages of PDAC and stage 1 to 2 PDAC, showing improved diagnostic performance in all cases compared to when CA19-9 was used alone.Un-beom Kang, Head of the Bertis Biomarker Research Institute and co-leader of the research, stated, “The results of this study represent a significant achievement in providing a useful diagnostic model for the early detection of pancreatic cancer, a particularly hard-to-treat cancer, based on Bertis’ advanced technologies in proteomics, bioinformatics, and machine learning. We are committed to follow-up research and development to ensure that healthcare professionals and patients can utilize this technology in clinical settings, thereby facilitating early diagnosis of pancreatic cancer.”Bertis is promoting the commercialization of its blood test, Panccheck®, to aid in the early diagnosis of pancreatic cancer based on this research achievement. Currently, a confirmatory trial is underway, with blood samples secured from 513 individuals, including 220 pancreatic cancer patients, in preparation for approval from the Ministry of Food and Drug Safety. Additionally, Bertis is developing an early diagnosis test for ovarian cancer, which has the highest mortality rate among gynecological cancers and lacks effective early detection methods. The marker panel development is complete, and a clinical trial for algorithm enhancement are planned.Seung-man Han, CEO of Bertis, emphasized, “Bertis is working to introduce multi-marker diagnostic solutions with improved accuracy based on more biomarkers for major diseases by adding the latest machine learning technology to the proteomics technology we have developed over the past decade. Building on our capability to commercialize Mastocheck, the world’s first proteomics-based blood testing for early breast cancer diagnosis, we are committed to providing effective early diagnosis solutions for hard-to-treat diseases like pancreatic cancer in clinical practice.”Meanwhile, Bertis combines proteomics and bioinformatics to develop innovative biomarkers for cancer and other major diseases, as well as provides diagnosis and analysis solutions. It succeeded in commercializing proteomics technology with Mastocheck®, the blood testing solution for early breast cancer diagnosis, and PASS (Pan-omics Analysis Service & Solution), an omics analysis solution. Bertis continues to conduct research on early diagnosis solutions for major diseases.

Bertis Joins the Ministry of Science and ICT’s‘Development of Technologies for Spatial Proteomics-BasedMulti-Omics Analysis’ Project- 6 institutions participate with a total research budget of approximately 9 billion KRW over 4 years and 6 months-Bertis participates in securing global-level spatial proteomics technologies with its expertise in proteomics-based biomarkersOn September 6, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced its participation as a research institution in the ‘Development of Materials and Component Technologies for Spatial Proteomics-Based Multi-Omics Analysis’ project (Project No. RS-2024-00454407), led by the Ministry of Science and ICT and the National Research Foundation of Korea.This project is part of the ‘2024 Nano and Materials Technology Development Project’ initiated by the Ministry of Science and ICT and the National Research Foundation of Korea. It aims to secure global-level technologies that will drive the creation of new industries and advance key sectors, while also expanding research infrastructure and promoting commercialization.Bertis will collaborate with the institution in charge of research, University of Ulsan College of Medicine, Meteor Biotech, Korea Animal Model Archive, Future Medicine Research Institute of CHA Bundang Medical Center of CHA University, and the Korea Basic Science Institute to form the 'Spatial Proteomics Technology Development Research Consortium.' The consortium will undertake the project to develop spatial proteomics technologies for multi-omics, with a total research budget of 9 billion KRW, until December 2028.Spatial proteomics technology is a field that studies the spatial distribution and interactions of proteins within tissues. No commercialized technologies for spatial proteomics analysis exist, and single-cell preprocessing methods are being used as alternatives. This project will develop novel materials and foundational technologies for protein digestion, which are currently unavailable in spatial proteomics processes. The goal is to establish the first global analysis platform, from tissue separation to diagnosis, build databases, develop AI software, and create biomarkers for various cancers.Bertis, recognized for its technological prowess in developing and utilizing proteomics-based biomarkers, will be responsible for establishing LC-MS analysis conditions using single-cells, developing spatial proteomics-specific preprocessing materials and POC (Proof of Concept), creating quality control software for fragmented tissue proteomics analysis platforms, and developing and training AI algorithms through pathology image analysis.Kyunggon Kim, a professor in the Department of Digital Medicine at the University of Ulsan College of Medicine, head of the institution in charge of research, stated, "Spatial multi-omics is increasingly recognized as a key platform for translational research and new drug development. However, spatial proteomics is a field that demands advanced technology and material development. We are excited to collaborate with outstanding government-funded research institutions, hospitals, and companies with core technologies, such as Bertis and Meteor Biotech to conduct challenging research.”Un-beom Kang, Head of Bertis Biomarker Research Institute and co-leader of the research, explained, “The field of proteomics has high technological utility and remarkable growth within the biotech industry, accompanied by intense global competition to secure technological superiority and foundational technologies for disease diagnosis and treatment. As a leader in the proteomics industry with expertise in commercializing technology and applying AI, Bertis is dedicated to achieving significant results in the development of spatial proteomics technologies through collaboration with leading domestic research institutions."Meanwhile, Bertis has established its proprietary analysis system for single-cell proteomics research and is accelerating the advancement of proteomics-based precision medicine technologies by utilizing AI. The company is enhancing the accuracy of early diagnostic solutions for breast cancer, pancreatic cancer, and ovarian cancer through machine learning-based algorithms. It is also developing the SAN (Spectrum is All you Need) model, which uses large language models (LLM) to analyze protein distribution data and extract health information related to the presence or absence of target diseases.

Bertis and Rokit Genomics Sign MoU for Collaboration on Proteomics and Genomics Analysis Services - Collaborating on single-cell proteomics and genomics analysis services to provide single-cell multi-omics analysis services and advance joint technology development <Photo: Bertis CEO Seung-man Han (left) and Rokit Genomics CEO Tae-woo Kwon commemorate the signing of the MoU.> On August 26th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it signed a Memorandum of Understanding (MoU) with Rokit Genomics, a single-cell analysis company (led by CEOs Tae-woo Kwon and Yoon-Ki Gil). Under this MoU, Bertis and Rokit Genomics plan to collaborate on the development and marketing of proteomics and genomics analysis services based on their expertise in single-cell analysis technology. They also will work together on future joint technology development. Single-cell analysis is a technique that distinguishes biological characteristics at the level of individual cells. It enables high-sensitivity and high-resolution analysis of rare cells or low-expressed genomics and proteomics. This method is utilized in various research fields including cancer, Alzheimer's, autoimmune diseases, and infectious diseases. The single-cell analysis market is expected to grow significantly, reaching approximately 19 trillion KRW globally by 2030. Single-cell proteomics analysis is a technology that qualitative and quantitative analysis of proteins at the single-cell level. This technique allows detailed analysis of disease-specific proteins, minimizing the loss of cellular diversity information that can occur in tissue or cultured cell analyses. This technology is expected to advance the application of precision medicine through cell-specific analysis. Bertis, which has secured the technology to analyze the proteome of trace samples through next-generation mass spectrometry technology, offers single-cell proteomics analysis of over 5,000 proteins and has launched Korea's first single-cell proteome profiling service based on this cutting-edge technology. Rokit Genomics provides customer-specific analysis services using single-cell genomics sequencing. Rokit Genomics focuses on cell heterogeneity, rare cells, cell lineage relationships, and biomarker discovery by analyzing genomic data collected from individual cells. Leveraging extensive experience with samples from human tissues to plants and animals, Rokit Genomics performs analyses across requests. Kwon Tae-woo, the CEO of Rokit Genomics, stated, “With the rise of genomics and proteomics technologies, there is an increasing demand for combined analytical methods in drug discovery and candidate development. Our collaboration with Bertis, which possesses expertise in proteomics analysis, will be a milestone in expanding Rokit Genomics' multi-omics analysis capabilities. We expect to lead the popularization of single-cell analysis through advanced customer-specific consulting.” Seung-man Han, the CEO of Bertis, emphasized, “As a leader in proteomics technology, we have equipped ourselves with the latest equipment and expertise to offer single-cell proteomics technology to domestic researchers. Through this service collaboration with Rokit Genomics, a pioneer in single-cell sequencing, we hope to raise awareness of single-cell proteomics analysis among bioindustry and academic researchers and to expand our collaborative technology development.” Furthermore, Bertis’ omics analysis solution, PASS (Pan-omics Analysis Service & Solution), provides customized proteomics analysis solutions for biomarker discovery, validation, drug research and development, and production based on client’s needs. The service caters to a range of clients, including biotech and CDMO enterprises developing new modality drugs, and has completed 103 projects for 54 clients as of July 2024, driven by satisfaction with data quality and customized consulting.

Bertis to Participate in Korea's Largest Proteomics Conference, KHUPO 2024 - Poster presentation on research outcomes in biomarker candidates for prostate cancer diagnosis, and an educational lecture on QC and interpretation of mass spectrometry-based proteomics data- Setup of a promotional booth from June 25 to 27 to introduce the mass spectrometry-based omics analysis solution PASS, and its customized peptide synthesis solution, PEPS PRO. On June 25th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in 'KHUPO 2024 YEOSU (KHUPO 2024)', the largest domestic proteomics conference hosted by The Korean Human Proteome Organization (KHUPO). <Image: Logos of KHUPO and Bertis> KHUPO 2024, to be held from June 25 to 27 at the Yeosu Expo Convention Center, is expected to be a platform for sharing new research achievements and innovative technologies in the field of proteomics under the theme "PROUD: PROteomics Unlimited Desire." As a leading domestic company in the proteomics field, Bertis will present research achievements, conduct educational sessions, and operate a promotional booth during KHUPO 2024.Dr. Jin-Young Cho from the Biomarker Research Team at Bertis R&D division will present a poster on "Novel Diagnostic Biomarkers for Prostate Cancer Discovered Using a Mass Spectrometry-Based Pipeline" on Wednesday, the 26th at 11:45 AM, and Thursday, the 27th at 11:30 AM. <Image: Discovery process of PCa biomarker candidates>Prostate Cancer(PCa) can often be detected by testing the levels of Prostate-Specific Antigen (PSA) in blood. However, the level of PSA is also rise in cases of benign prostatic hyperplasia and prostatitis, necessitating a more accurate diagnostic test specifically for PCa. In this study, the Bertis team used liquid chromatography data-independent acquisition tandem-mass spectrometry (LC-DIA-MS/MS) to analyze the human serum of 50 healthy controls (HCs), 42 individuals with benign conditions, and 90 patients with PCa. The aim was to discover potential biomarkers for PCa diagnosis. They identified 24 differentially expressed proteins (DEPs) in PCa patients compared to healthy controls and those with benign conditions. In addition, bioinformatic analysis on public data of prostate cancer-associated biomarkers and prognosis before and after treatment, a list of 50 proteins was created. Takes together, a total of 74 serum proteins were selected as potential prostate cancer biomarker candidates.In the education session, Dr. Sunghyun Huh, Head of the Bioinformatics Team at Bertis R&D division will deliver a lecture titled “Interpretation of Mass Spectrometry-Based Proteomics Data for Biological Research”. The session will introduce the analysis, processing, and interpretation of mass spectrometry-based proteomics data, covering relevant research examples. The lecture is scheduled for Wednesday, the 26th, at 9:00 AM in the 1st floor lecture hall, as the first session of ‘Education Session 3: Proteomics meets AI’During the event, Bertis will operate a promotional booth to showcase its mass spectrometry-based omics analysis solution, PASS (Pan-omics Analysis Service & Solution), alongside its customized peptide synthesis service, PEPS PRO. PEPS PRO provides synthesis services for customized peptides, PNAs, and various organic compounds utilizing the company’s GMP facilities and highly skilled professionals, ensuring high-quality products at competitive prices. The company plans to utilize the KHUPO 2024 platform to initiate a marketing campaign to promote PEPS PRO.Seung-man Han, CEO of Bertis, stated, "Bertis is advancing and commercializing proteomics technologies to contribute to the development of practical solutions in clinical settings for domestic biotech companies." He further emphasized, "We are dedicated to sharing innovative technologies and research outcomes to broaden the impact of proteomics in Korea and bolster technological competitiveness."

Bertis, Successful in Clinical Proteomics Technology Commercialization,Seeks International Business Partners at BIO USA 2024 - Participating in the world's largest bio conference, hosted by the Biotechnology Innovation Organization (BIO), from June 3-6 to explore business development opportunities with global bio and pharmaceutical companies. - Aiming to secure international business partners for proteomics-based early diagnostic tests through the 'Seoul Bio Forum' on June 3 and the 'Company Presentation' on June 5. On May 28th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in the world's largest bio conference, the 'BIO International Convention 2024' (BIO USA 2024), held at the San Diego Convention Center in the United States from June 3 to 6. At BIO USA 2024, where leading companies, research institutions, and investors from the global bio industry will gather, Bertis will conduct two company presentations. These presentations will highlight advancements in clinical proteomics technology and share the latest research developments and business achievements of Bertis, including their successfully commercialized proteomics-based early diagnostic test. Through these activities, Bertis aims to explore various business development opportunities with global bio and pharmaceutical companies. [Image] Bertis Bio USA 2024 Presentation Schedule The first company introduction presentation will take place on June 3rd, local time (PST), at 6:00 PM at the Aquillius Innovation Hub as part of the 'Seoul Bio Forum,' organized by Invest Seoul, Seoul BioHub, and others. The event is dedicated to fostering networking opportunities among Korean enterprises engaged in BIO USA 2024, venture capital firms seeking U.S. market entry and investment, and bio-tech and legal entities possessing the requisite expertise for U.S. expansion. Bertis will showcase its proteomics-based early diagnosis solution technology and outline its growth strategy. On the third day of the event, June 5th at 2:30 PM, Bertis will conduct a Company Presentation session at Hall A Company Presentation Theater4. During this session, Bertis will introduce its successfully commercialized proteomics-based early diagnostic blood test pipeline and its mass spectrometry-based omics analysis service PASS (Pan-omics Analysis Service & Solution) to global bio-pharmaceutical companies. The company aims to explore opportunities for overseas business partnerships and collaborations through this session. Seung-man Han, the CEO of Bertis, stated, "Proteomics will play a crucial role in addressing major challenges facing the medical and healthcare sectors worldwide, enabling precision medicine. Through this event, Bertis aims to share the excellence and commercial viability of our core technology. We also strive to secure business cooperation opportunities to accelerate the introduction of proteomics-based technologies and products into clinical practice." Furthermore, Bertis leads technological innovation in the field of clinical proteomics by leveraging ProteoID, its core technology framework spanning protein data analysis to product and service commercialization. In 2019, Bertis achieved the world's first commercialization of a proteomics-based early diagnostic blood test for breast cancer, MASTOCHECK®, in both domestic and Singaporean markets, conducting a cumulative total of 170,000 tests in South Korea. Currently, they are advancing the development of early diagnostic tests for pancreatic and ovarian cancers as part of their pipeline expansion.

Asia Proteomics Leader, Bertis, Participates in' Asia Summit on Global Health 2024' -Invited as the only Korean company to participate in the event hosted by the Hong Kong Special Administrative Region on May 16-17... Dr. Sangtae Kim, Chief Scientist of Informatics and AI, will attend as a speaker. -Sharing insights on proteomics technologies and applications that Asia should focus on, including early cancer detection blood tests, during the session on ‘Advancing Healthcare in Asia Through Innovation’ on May 17 [Image] Asia Summit on Global Health, Bertis Logo On May 16th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in the '4th Asia Summit on Global Health 2024 (ASGH 2024)', which will be held at the Hong Kong Convention and Exhibition Center (HKCEC) on May 16th and 17th.ASGH, jointly organized by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), aims to promote innovative medical technology development and support investment activation to seek a more sustainable future amid global issues such as aging population, novel infectious diseases, and climate-related health threats.At ASGH 2024, key officials from the governments of China and the Hong Kong Special Administrative Region, as well as executives from global leading pharmaceutical and biotech companies and research institutions, buyers, and investors active in the Asian region, will participate. Themed ‘Innovation, Inclusion, Impact’, ASGH 2024 will compromise a series of thematic sessions focusing on the latest trends in different medical sectors. Project pitching and deal-making meetings will also be organized to facilitate business discussions and investment partnerships. Bertis, as a leader in Asia's proteomics, is invited as the only Korean company to participate. Dr. Sangtae Kim, Chief Scientist of Informatics and AI at Bertis, will speak, introducing proteomics technologies that Asia's medical industry should focus on for development, and will share insights into their applications and importance.Dr. Kim will participate in the session titled 'Advancing Healthcare in Asia Through Innovation' on May 17th. He will highlight how proteomics technology is rapidly advancing and providing opportunities for precise disease diagnosis, personalized treatment tailored to individuals, and drug target discovery. Particularly, he will introduce proteomics-based early cancer detection blood tests as an innovative technology that will bring significant changes to the healthcare industry in Asia. He plans to emphasize the importance of investing in and leading the development of proteomics technology and industry in the Asian region.Dr. Kim stated, "I am honored to have the opportunity to discuss the future direction of Asian healthcare with global leaders in Hong Kong, the hub of Asia. Proteomics technology is essential for realizing precision medicine and plays a crucial role in addressing key challenges faced by the healthcare sector in Asia. I will do my utmost to promote regional collaboration and highlight the importance of this technology in overcoming these challenges."Bertis combines more than a decade of accumulated expertise in proteomics with bioinformatics to identify biomarkers for various major diseases, including cancer. These biomarkers are then utilized in the development of diagnostic and analytical solutions. In 2019, Bertis introduced MASTOCHECK®, the world's first proteomics-based early breast cancer detection blood test. The company is currently working on developing early detection blood tests for pancreatic cancer and ovarian cancer as part of its ongoing pipeline. Additionally, Bertis is engaged in the research and development of SAN (Spectrum is All you Need) model, aiming to create an innovative health information interpretation model that can extract health insights from proteomic biological data using AI technology.

Bertis Presents Research Findings on Candidate Protein Biomarkers for Precision Diagnosis of Ovarian Aging at International Conference -At the 3rd Reproductive Aging Conference held in Cancun, Mexico from May 1st to 4th, Bertis unveiled research findings on protein biomarkers involved in ovarian aging.-The biomarkers expected to be valuable for evaluating ovarian aging, directly associated with the health span of postmenopausal women. On May 9th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it has unveiled research results identifying protein biomarker candidates involved in ovarian aging at the 3rd Reproductive Aging Conference held in Cancun, Mexico from May 1st to 4th.Ovaries are one of the organs that age most rapidly in the body. As individuals age, the number of oocytes, the immature precursors to eggs, decreases continuously, and their quality deteriorates. This is a significant factor contributing to infertility problems in modern societies where advanced maternal age pregnancy is common. Moreover, ovarian aging is thought to be directly proportional to postmenopausal health span. Hence, accurate monitoring and prediction of ovarian aging is paramount to personalized fertility.Bertis research team in this study presented 12 protein candidate biomarkers derived from genes specifically expressed in oocytes, which decrease in expression with increasing age in the ovaries. Additionally, they identified two proteins of them showing significant differences in expression levels between women in their 20s and 30s, suggesting these proteins as useful biomarker candidates not only for evaluating oocyte numbers but also for assessing their quality.The ‘Reproductive Aging Conference,’ in which Bertis participated, is an international conference that focuses on the significant impact of reproductive organ tissue aging on human aging, sharing related research trends and achievements. At this conference, Bertis presented research findings on the topic of ‘Systematic Mining of Potential Biomarkers for Ovarian Reserve Using Multi-omics data sets’ through a poster presentation.Dr. Sunghyun Huh, Head of the Bioinformatics Team at Bertis Biomarker Research Institute, who led the study, remarked, "If we can precisely diagnose the degree of ovarian aging in women, it will not only enable more effective management of infertility but also lead to personalized approaches to women's health in the future." He added, "We will continue to pursue research necessary to apply Bertis' advanced proteomics technology to aging studies, aiming to introduce technologies that can be utilized in clinical settings."Currently, some ovarian reserve tests have been introduced, such as measurement of plasma AMH (Anti-Mullerian Hormone) or ultrasound imaging of AFC (Antral Follicle Count). neither of these tests directly represents the quantity of oocytes, and assessing the quality of oocytes, which is closely related to age, is also challenging. The research team attempted a systematic approach to identify potential biomarkers for ovarian reserve by integrating public datasets including transcriptomics and proteomics of ovarian tissues, cells, and biofluids, aiming to directly confirm the quantity and quality of oocytes. <Image: Expression Patterns of Biomarkers of Oocyte Quantity and Quality>To identify biomarkers for assessing the number of oocytes, the research team first selected 4,227 genes from a total of 17,769 genes in the GTEx dataset, showing decreased expression in the ovaries with increasing age. Among these, they narrowed down to 33 genes specifically expressed in the ovaries compared to other tissues. Finally, they confirmed 12 protein candidate biomarkers derived from 12 genes specifically expressed in oocytes as the final candidates.Furthermore, to determine if the candidate biomarkers could also assess the quality of oocytes, they conducted single cell RNAseq analysis to compare the expression levels of candidate biomarkers in oocytes from average women in their 20s and 30s. As a result, two protein biomarkers among the candidates showed significant differences in expression levels between women in their 20s and 30s, suggesting their utility not only in evaluating oocyte numbers but also in assessing their quality.Moreover, in terms of detectability of the protein biomarkers, six out of the 12 candidate protein biomarkers including two biomarkers indicating the quality of oocytes, were found in public blood protein datasets and in in-house serum spectral library. It means subset of candidates show detectability in the blood proteome. Therefore, in subsequent studies, the research team plans to confirm the expression levels of these candidate biomarkers during blood protein analysis to determine whether they can be used as indicators of ovarian aging.Amidst worldwide anti-aging research and product development efforts, Bertis is conducting aging research using a proteomics-based approach. Leveraging its unparalleled protein profiling capabilities and a library of protein quantification analysis built over a decade of research, Bertis continues its efforts to discover markers useful for diagnosing diseases resulting from aging and developing treatments.

Bertis Renews Mass Spectrometry-basedOmics Analysis Service 'PASS' - Incorporating insights from two years of customer needs and staying abreast of the latest research and technological advancements. - Enhancing tailored services for clients in areas such as R&D, biotechnology, and pharmaceuticals.On April 4th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced the renewal of their PASS (Pan-omics Analysis Service & Solution), which provides mass spectrometry-based omics analysis service. This renewal reflects both customer needs and the latest research and technological trends.Pan-omics is the integration of complex “omics” datasets generated from the subfields of genomics, transcriptomics, proteomics, and metabolomics to increase the understanding of pathophysiology, diagnosis, and treatment of diseases. PASS, under the slogan 'Through PASS to PATH', is an insightful analysis solution leveraging Bertis’ pan-omics knowledge and know-how coupled with its proprietary bioinformatics and AI technology to deliver analytical services including protein biomarker discovery, validation, drug research and development, production, and more. Bertis announced the renewal of their PASS, which provides mass spectrometry-based omics analysis service.This renewal reflects both customer needs and the latest research and technological trends.The recent overhaul of the PASS service was driven by a commitment to align with customer needs and the latest research, and technological advancements observed over the two-year period since its launch in May 2022. Whereas the previous iteration comprised four services centered around foundational protein research and its secured technologies, the revamped PASS offers a more structured service portfolio, ranging from analytical services essential for research to analysis package solutions required for research and development in the biopharmaceutical sector. As a result, the augmentation of tailored services, specifically catered to the objectives of each client, such as biotech firms pioneering novel modalities like exosomes and PROTAC, as well as CDMO enterprises, has been notably reinforced.The renewed PASS service is structured around five core components, each designed to meet specific analytical needs. INTEGRATED PROTEOMICS provides qualitative and quantitative analysis of whole proteomes. TARGETED PROTEOMICS facilitates quantitative analysis of target proteins using the MRM/PRM methods, while SINGLE CELL PROTEOMICS offers qualitative and quantitative analysis of proteins in single cells. LIPIDOMICS provides qualitative and quantitative analysis of lipids using 20 standards, BIOINFORMATICS enables the bioinformatics-based proteomic data analysis and interpretation. For more information on the service process and updated FAQs about PASS, please visit the service introduction page on the Bertis website at https://bertis.com/ko/solution/pass.phpSeong-jun Park, Director of the PASS Center, emphasized, "In the past year, PASS has strategically pursued a diverse range of projects and diligently uncovered market demand, resulting in a revenue growth of over two-fold compared to the preceding year. With a commitment to delivering superior, tailored solutions to our clients, we have undertaken a comprehensive renewal initiative." He continued, "We aspire for PASS services to serve as a catalyst for expediting the development of new pharmaceuticals and products, empowering enterprises to efficiently access a wealth of diverse and precise protein data."

Bertis Secures 20 Billion KRW in Pre-IPO Investment- Pre-IPO round participation from Current and New Investors, reflecting Growth in Early Breast Cancer Detection Blood Tests and Analytical Services,Anticipation for Future Offerings On February 26th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it has successfully secured a pre-IPO investment of 20 billion KRW. The investment involved participation from existing and new investors, including △KDB Bank △Winvest Venture Capital △Premier Partners △BNH Investment △Dream CIS.The successful closure of this investment round reflects the growth of Bertis' commercializing breast cancer early detection blood test, MASTOCHECK®, along with its analysis service, PASS (Pan-omics Analysis Service & Solution). The positive outlook also underscores expectations for forthcoming early detection blood test products targeting pancreatic cancer, ovarian cancer, and other pipelines. Bertis intends to utilize the investment capital to propel the commercialization of its early detection blood test products, broaden its analysis service portfolio, and expand its global footprint, thereby fortifying its business foundation and advancing its technological prowess.Founded in 2014, Bertis has dedicated over a decade to research and development, enhancing protein identification and quantification technologies and establishing globally competitive capabilities in protein data analysis and interpretation. Leveraging this expertise, in 2019, Bertis introduced MASTOCHECK, the world's premier proteomics-based blood test for early breast cancer detection. Last year alone, Bertis serviced over 100,000 examinations, with a cumulative total exceeding 170,000 cases.Furthermore, in May 2022, Bertis introduced the Pan-omics Analysis Service & Solution (PASS), providing analytical solutions essential for protein analysis, biomarker discovery and validation, as well as drug development and clinical research processes. Through the PASS service, Bertis has garnered projects from a total of 53 organizations, including pharmaceutical companies, government-funded institutions, and research centers, showcasing its ability to commercialize proteomics technologies.Bertis Co-CEO Seung-man Han remarked, "This investment signifies a pivotal moment for Bertis, acknowledging our steadfast technological advancements and promising business outlook, thereby catalyzing our business initiatives." He added, "Moving forward, we are committed to effectively commercializing diagnostic test pipelines in domestic and international markets, broadening the spectrum of analysis services to specialize in Exosome and PROTAC therapy, and delivering tangible commercial results."

Breast Cancer Early Detection Blood Test 'MASTOCHECKTM'Expands to 7 Countries in Saudi Arabia and the Middle East - Bertis Signs Co-promotion and Distributorship Agreement for MASTOCHECKTM with SaudiVax During the State Visit of the President of South Korea to Saudi Arabia-CEO Seung-Man Han stated, "Due to the high demand for the blood test method and the presence of a nationally led medical delivery system in the region, we are committed to establishing a stable testing delivery system." On October 30th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it has entered into a co-promotion and distributorship agreement for its early breast cancer detection blood test, MASTOCHECKTM, with the Saudi biotechnology firm, SaudiVax Inc., in Saudi Arabia.Through this agreement, SaudiVax will be responsible for sales and marketing of MASTOCHECK in seven countries, including Saudi Arabia, Bahrain, Kuwait. They will also manage the collection and delivery of blood samples for testing in medical institutions within those countries. Bertis will conduct the samples analysis and deliver the test results. Additionally, Bertis will provide necessary support for MASTOCHECK sales and marketing, including handling regulatory approvals, marketing, medical staff training, and patient information dissemination. In addition, this agreement was signed on the occasion of the state visit of the President of South Korea to Saudi Arabia from the 21st to the 24th, as well as the visit of the South Korean business delegation. Through this agreement, the two parties have agreed to simultaneously launch Bertis' developed products, including blood tests for early detection of pancreatic cancer, in seven Middle Eastern countries alongside their domestic commercialization. SaudiVax is a joint venture between a Saudi Arabian healthcare company UYC, and U.S.-based PnuVax, which supplies biologics to the Gulf Cooperation Council (GCC) and countries within the Organization of Islamic Cooperation (OIC). Furthermore, the company is actively supporting the Saudi Vision 2030 project, a comprehensive initiative led by Crown Prince Mohammed bin Salman aimed at economic diversification, global engagement, and enhanced quality of life. The company is dedicated to fostering the establishment of the life sciences industry within Saudi Arabia as part of this broader effort.Dr. Mazen Hassanain, co-founder and managing director of SaudiVax, stated, "Blood-based cancer screening tests are considered advanced technology that aligns with Saudi Arabia's goals in the health sector, including improving healthcare accessibility, through the Saudi Vision 2030 project. It is expected to contribute to the enhancement of public health and the development of biotechnology” he added, “We are committed to making our best efforts to facilitate the introduction of MASTOCHECK based on our supply system and expertise, ensuring that patients in need of MASTOCHECK can undergo testing smoothly."Seung-Man Han, the CEO of Bertis, stated, “Due to the gap in medical services accessibility among regions and factors related to religious and cultural differences, there is a high demand for early blood-based cancer diagnostic tests in key Middle Eastern countries. Introducing MASTOCHECK to these countries is a positive step forward.” He further mentioned, “As these countries take the lead in providing medical services, we expect the testing process to be activated rapidly from the early stages. We are going to put the best effort to establish a stable testing delivery system to ensure reliable test services for the patients.”MASTOCHECK is a blood test method that allows for convenient early screening of breast cancer. It quantitatively measures three specific protein biomarkers closely associated with breast cancer within the blood. The quantified biomarkers’ values are then analyzed using a patented proprietary algorithm to enable early detection of breast cancer. Bertis is currently developing early screening blood tests for pancreatic cancer and ovarian cancer as part of their follow-up pipeline. For pancreatic cancer early diagnostic solution, the product development has been completed including marker panels, algorithms, IVD software, and reagents. Currently the product is going through confirmatory clinical trial. Regarding ovarian cancer, the marker panel development has been completed and are planning clinical trials for algorithm enhancement.

BERTIS Joins 2023 Pink Festival of Pink Ribbon Campaign - In celebration of the Breast Cancer Awareness month in October, Bertis serves as a sponsor of the event to raise awareness of early detection and regular check-up of the disease. [Image] 2023 Pink Festival logo, Bertis logo Bertis, a company specializing in the development of proteomics-based precision medicine technology company (led by CEOs Dong-young Noh and Seung-man Han), announced on October 13th that it will participate in the 2023 Pink Festival at the Officers’ Quarters 5 in Yongsan on October 15th, to promote awareness of early detection and regular checkup of breast cancer. Marking its 23rd year, the Pink Festival is hosted by the Korea Breast Cancer Foundation, Korean Cancer Society, Korean Breast Cancer Society as part of the Pink Ribbon Campaign to raise awareness about a healthy lifestyle for breast health and breast cancer prevention. This year’s event will offer five fitness programs helpful for women’s health and breast health, such as Dance Fit, Piloxing, Pound Fit, Latin Fit and a 3km group run, approximately 1,000 people selected through pre-registration will participate. In celebration of Breast Cancer Awareness Month in October, Bertis will sponsor the 2023 Pink Festival and operate a promotional booth at the event. Along with hosting a quiz to help the participants understand the importance of regular breast checkups for early breast cancer detection, Bertis will provide essential information for regular breast cancer screenings, including an introduction of MASTOCHECK®, a blood test solution for early breast cancer diagnosis. MASTOCHECK® is the world’s first proteomics-based blood test solution for early breast cancer detection developed by Bertis. With its effectiveness in diagnosing stage 0-2 breast cancer has been verified in Korea, leading to its approval as an in vitro diagnostic medical device by the Ministry of Food and Drug Safety in 2019. As of October 2023, it is utilized by as many as 392 hospitals and health examination centers in Korea. Bertis CEO Seungman Han said, “As a company that offers a solution for early breast cancer detection and takes a leading role in promoting breast health awareness, our participation in this event is of great significance. While we concentrate on developing technologies essential for precision medicine, targeting major diseases, including breast cancer, we are committed to enhancing public awareness that the early detection and regular checkups.”

Bertis to Present 10 Research Outcomes at HUPO 2023,Including Development of Next-generation Analysis Methodfor Proteomic Data- HUPO, one of the world's largest proteomics societies, is returning to Korea for the first time in 16 years to be held at BEXCO, Busan from September 17 to 21- Bertis joins as a major sponsor in the event which attracts over 1,000 scholars and key industry officials from 40 countries- Bertis presents 10 studies, including the development of next-generation mass spectrometry and single-cell proteomic analysis, and highlights its core technology framework, ‘ProteoID’, as well as nine essential technologiesBertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced on September 7 that it would participate in ‘2023 HUPO, Human Proteome Organization’, one of the largest international academic gatherings in the field of proteomics. The event will take place from September 17 to 21 in Busan, Korea.HUPO 2023, themed 'Together Through Proteomics,' is scheduled to be held at BEXCO in Busan. The event is expected to draw over 1,000 researchers and prominent figures from more than 40 countries. This annual event, inaugurated in France in 2002, has been held continuously, rotating through the Americas, Asia, Oceania, Europe, and Africa. It now returns to Korea after 16 years since its last appearance in Seoul in 2007During the event, Bertis will deliver presentations on 10 studies, including the development of next-generation mass spectrometry and single-cell proteomic analysis methodologies. The three main topics Bertis will cover in oral presentations are ▲ Broad Target Scanning (BTS) - a pragmatic LC-MS acquisition method for collecting population-scale real-world proteomics data ▲ Identification of Secreted Unannotated Small ORF Microproteins from Adipocytes and in Plasma to Elucidate Function of Novel Gene Product Proteins ▲ Spatial proteomic approaches for triple-negative breast cancer on single-cell resolution. In addition, the company will provide seven poster presentations on DeepMRM: Deep learning-based object detection model for proteomics data, Exploring the Human Aging Blood Proteome, and others. <Image> List of Bertis’ oral presentations to be delivered at HUPO 2023(See the overview of presentation details below)Seung-man Han, CEO of Bertis, said, “It is encouraging for the Korean proteomics industry and academia that the representative academic event in the proteomics field is held in Korea at this critical juncture when the use cases of proteomics technology are rapidly increasing across all areas of the bio industry. Bertis will also leverage the upcoming HUPO 2023 as an opportunity to introduce Korea's technologies to the global proteomics community and make its utmost efforts to contribute to substantial breakthroughs in the development of proteomics technology.Bertis plans to focus on promoting protein data analysis and interpretation capabilities, as well as know-how in technological commercialization through HUPO 2023. The company will set up a large promotional booth inside the conference hall to introduce nine core technologies related to biomarker discovery and algorithm development, diagnostic service commercialization, and advanced technology. The primary focus will be on the core technology framework ‘ProteoID(Proteome Integrated Determination)’. Furthermore, it will publicize its pipeline of multi-marker solutions for early diagnosis, including ‘MASTOCHECK®’, an early diagnosis blood test for breast cancer, and PASS (Pan-omics Analysis Service & Solution). <Image> ProteoID, Bertis’ core technology system, and nine essential technologiesThe name ProteoID is derived from the term 'proteoid roots,' which refers to the densely packed roots of plants. It implies the interactions among proteins, combinations of various disease markers, and the organic blend of proteomics technologies. Bertis is fully committed to realizing the potential of proteomics in clinical and medical contexts based on ProteoID, a technology system that encompasses all stages of utilizing proteomics technology, from protein data analysis to product and service commercialization.

Bertis Pan-omics Analysis Solution and Systems (PASS) launched in the U.S.- Bertis, Inc.’s wholly owned US subsidiary, Bertis Bioscience, signed its first service agreement with the world-renowned Salk Institute for Biological Studies, to provide a PASS service using its CLIA lab and proteomics experts in San Diego, California.- In Korea, Bertis, Inc., already launched PASS in May 2022, offering a robust suite of analytical services including protein identifications, biomarker discovery and drug target discovery analytical services.Bertis (Co-CEOs Dong-Young Noh and Seung-Man Han), a proteomics-based precision medicine company announced the launch of PASS (Pan-omics Analysis Service) service in the United States through its wholly owned US subsidiary, Bertis Bioscience Inc.Pan-omics is the integration of complex “omics” datasets generated from the subfields of genomics, transcriptomics, proteomics and metabolomics to increase the understanding of pathophysiology, diagnosis and treatment of diseases. PASS is an insightful analysis solution leveraging Bertis’ pan-omics knowledge and know-how coupled with its proprietary bioinformatics and AI technology to deliver analytical services including the core protein identification and biomarker discovery but also drug development and clinical research processes.<Image> PASS LogoIn the US, Bertis’ wholly owned US subsidiary, Bertis Bioscience, has launched the much-anticipated PASS services after more than a year of preparation to assemble industry recognized experts in both mass spec-based proteomics as well as bioinformatics. The US PASS services will be provided at its CLIA Lab in San Diego. As part of the US PASS offerings, Bertis Bioscience will initially offer proof-of-principle studies for protein biomarker discovery using Seer’s proteograph and nanoparticle kits.On June 8, 2023, Bertis Biosciences signed its first proteomics-based analysis service agreement in the United States with the Salk Institute for Biological Studies, a San Diego-based non-profit life science research center. The Salk Institute is known for life-changing discoveries in the fields of cancer, neuroscience, aging, immunobiology, and plant biology. Six Nobel Prize winners conducted research at Salk, one of the world's leading research centers. Under this agreement, Bertis Bioscience will provide proteomic data analysis to look for novel human disease biomarkers.Han Seung-man, CEO of Bertis, said, "We are pleased with the market’s enthusiastic reception of our PASS service launched just last year. We attribute the success to the market’s recognition of Bertis’ proprietary technology and know-how in proteomics analysis and commercialization. Our technology and services have shown strong global competitiveness and receive favorable reception at various international conferences. We believe the US will provide a stage for us to showcase our expertise globally and build our PASS business by serving world-class research institutions as a start.”Amid the increasing demand for multiomics analysis data, PASS has received significant attention from industries such as biotech, pharmaceutical companies, and research institutes since its launch in Korea in May 2022. Leveraging its state-of-the-art analysis system and industry leading proteomics expertise, as of June, Bertis Inc. signed agreements for PASS with twenty companies, including national institutions, government-funded research institutes, and private companies.

Bertis Publishes Findings on ‘DeepMRM’, a Targeted ProteomicsData Interpretation Software Package in International Journal-Publish findings on assessing the performance and accuracy of the self-developed ‘DeepMRM’ in ‘Cell Reports Methods’, an international journal, on July 12-According to the results of the comparative test on the performance of discovering protein candidates, DeepMRM has higher accuracy than existing software and has the lowest error percentage-Promote high-speed analysis in the clinical environment and improve reproducibility and scalability of targeted proteomics analysisOn July 12, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it had presented its findings on assessing the performance of ‘DeepMRM’, a software package based on deep learning algorithms for object detection, in ‘Cell Reports Methods’.‘DeepMRM’ is a software package which the Bertis research team has developed by employing deep learning technology with the aim of more efficiently and accurately conducting MRM (Multiple Reaction Monitoring), a representative analysis method for discovering targeted protein candidates. With an existing community standard tool for MRM, researchers often devote substantial time to manual data interpretation, which hinders the transferability, reproducibility, and scalability of this approach. Deep MRM addresses these limitations by utilizing deep learning technology for object detection.The Bertis Machine Learning team and its U.S. subsidiary Bertis Bioscience team utilized public MRM dataset to test the performance of DeepMRM against the most widely used Skyline. The results demonstrated that DeepMRM outperformed Skyline in both correlation coefficient between quantification values and actual values of analyzed proteomes, and MAAPE (Mean Arctangent Absolute Percentage Error), which measures average error values. Even when applying the mProphet algorithm, a filter that allows skyline to make the results more refined, DeepMRM's results were more accurate.><Image: Table comparing the performances of DeepMRM and existing software>With its superior performance, DeepMRM not only reduces proteomic analysis time in clinical research, but also improves the reproducibility of analysis results, increasing the reliability of results. In addition, thanks to its high scalability, DeepMRM can analyze other types of proteins, such as PRM (ParallelReaction Monitoring) and DIA (Data-Independent Acquisition) data, in addition to MRM data.<Image: Process for analyzing targeted proteomics using DeepMRM>Jungkap Park, Director of Machine Learning team at Bertis, said, “DeepMRM is an innovative analysis tool that can dramatically increase data throughput in Bertis' major research areas - multi-biomarker diagnostic solutions and analysis services. Bertis will continue its R&D efforts towards AI-powered analytical tools to develop a unique platform which enables the diagnosis and treatment of diseases and the discovery of targeted candidates for new drugs in the future.”Seung-man Han, CEO of Bertis, said, “In our attempts to overcome the limits of proteomics data interpretation by integrating bioinformatics and AI technologies with proteomics technology, the publication of a paper on DeepMRM holds great significance. As a leader in proteomics in Asia, Bertis will spare no efforts in developing innovative technologies that can fully unlock the potential of proteomics in R&D and actual clinical applications.”Bertis is devoting itself to a project to eliminate limitations on interpreting and using proteomics data by incorporating proteomics technology accumulated over 10 years with bioinformatics and AI technologies. In particular, the company is making R&D efforts for the SAN (Spectrum is All you Need) model with a view to developing an innovative health information interpretation model which can produce health information from proteomic biometric information by automating the information processing and interpretation process.